Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo

Clinical and Experimental Immunology

Volumn 172, Issue 3, 2013, Pages 500-506

  Yasuda, S ^a   Sho, M ^a   Yamato, I ^a   Yoshiji, H ^a   Wakatsuki, K ^a   Nishiwada, S ^a   Yagita, H ^b   Nakajima, Y ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Anti angiogenesis; Anti tumour immunity; Immune checkpoint; PD 1; VEGFR2

Indexed keywords

MONOCLONAL ANTIBODY DC101; PROGRAMMED DEATH 1 RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UPREGULATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROGRAMMED CELL DEATH 1 RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84876717683     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12069     Document Type: Article

References (37)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-271.
2. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-1068.
3. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-258.
4. Hodi FS, O'Day SJ, McDermott DF etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
5. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515-548.
6. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22:265-268.
7. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-3895.
8. Nomi T, Sho M, Akahori T etal. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-2157.
9. Ohigashi Y, Sho M, Yamada Y etal. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11:2947-2953.
10. Berger R, Rotem-Yehudar R, Slama G etal. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-3051.
11. Brahmer JR, Tykodi SS, Chow LQ etal. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
12. Topalian SL, Hodi FS, Brahmer JR etal. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
13. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-10934.
14. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2:S127-133.
15. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
16. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
17. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-3736.
18. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101:937-949.
19. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-6180.
20. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003; 94:751-756.
21. Manning EA, Ullman JG, Leatherman JM etal. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007; 13:3951-3959.
22. Prewett M, Huber J, Li Y etal. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59:5209-5218.
23. Yoshiji H, Kuriyama S, Yoshii J etal. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004; 39:1517-1524.
24. Yoshiji H, Kuriyama S, Hicklin DJ etal. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001; 33:841-847.
25. Youngnak P, Kozono Y, Kozono H etal. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003; 307:672-677.
26. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19:813-824.
27. Wei YQ, Huang MJ, Yang L etal. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001; 98:11545-11550.
28. Niethammer AG, Xiang R, Becker JC etal. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8:1369-1375.
29. Luo Y, Zhou H, Krueger J etal. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006; 116:2132-2141.
30. Dirkx AE, oude Egbrink MG, Castermans K etal. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20:621-630.
31. Huang X, Wong MK, Yi H etal. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 2002; 62:5727-5735.
32. Suzuki H, Onishi H, Wada J etal. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol 2010; 40:197-203.
33. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308.
34. Woo SR, Turnis ME, Goldberg MV etal. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72:917-927.
35. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-3551.
36. Yamato I, Sho M, Nomi T etal. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009; 101:1709-1716.
37. Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1). Cancer 2010; 116:1027-1032.